Costimulation with anti-cluster of differentiation 3 and anti-cluster of differentiation 28 reduces the activity of mucin 1-stimulated human mononuclear cells

Wright,Stephen  E.; Rewers‑Felkins,Kathleen  A.; Quinlin,Imelda; Zohra,Fatema; Ahmed,Jewel

doi:10.3892/ol.2015.3840

Costimulation with anti-cluster of differentiation 3 and anti-cluster of differentiation 28 reduces the activity of mucin 1-stimulated human mononuclear cells

Authors:
- Stephen E. Wright
- Kathleen A. Rewers‑Felkins
- Imelda Quinlin
- Fatema Zohra
- Jewel Ahmed
View Affiliations

Affiliations: Department of Internal Medicine, Women's Health Research Institute, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA
Published online on: October 29, 2015 https://doi.org/10.3892/ol.2015.3840
Pages: 461-465

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cytotoxic T-lymphocyte activation and extension of the cell life span is necessary in order to enable immunotherapy to perform effectively against cancer. In the present study, mucin 1 (MUC1)-stimulated human mononuclear cells (M1SHMCs) were costimulated with bead-attached monoclonal antibodies specific for cluster of differentiation (CD)3 and CD28 receptors. The study was undertaken to determine whether costimulation was capable of enhancing the killing of cancer cells in vitro and of protecting non‑obese diabetic severe combined immunodeficient mice from tumor development. Lysis of MCF‑7 tumor cells by M1SHMCs was reduced following costimulation with anti‑CD3 and anti‑CD28. Furthermore, costimulation with anti‑CD3 and anti‑CD28 eliminated the protective effects of M1SHMCs on MCF‑7 breast cancer cell growth in the non‑obese diabetic severe combined immunodeficient mice. The present study suggested that costimulation with anti‑CD3 and anti‑CD28 is not advisable following antigen activation of lymphocytes under the conditions used here. Using a lower anti‑CD3/CD28 bead to T‑cell ratio may prevent immune suppression, however, further studies are required to support this hypothesis.

View Figures

View References

1	Barrett DM, Singh N, Porter DL, Grupp SA and June CH: Chimeric antigen receptor therapy for cancer. Annu Rev Med. 65:333–347. 2014. View Article : Google Scholar : PubMed/NCBI
2	Lechler R and George AJT: 21. Transplantation and rejection: Immunology. Roitt I, Bristoff J and Male D: Immunology (5th). (Philadelphia, NJ). Mosby. 1998.
3	Boise LH, Minn AJ, Noel PJ, et al: CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity. 3:87–98. 1995. View Article : Google Scholar : PubMed/NCBI
4	Riddell SR and Greenberg PD: The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods. 128:189–201. 1990. View Article : Google Scholar : PubMed/NCBI
5	Levine BL, Ueda Y, Craighead N, Huang ML and June CH: CD28 ligands CD80 (B7-1) and CD86 (B7-2) induce long-term autocrine growth of CD4⁺ T cells and induce similar patterns of cytokine secretion in vitro. Int Immunol. 7:891–904. 1995. View Article : Google Scholar : PubMed/NCBI
6	Levine BL, Cotte J, Small CC, et al: Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation. J Hematother. 7:437–448. 1998. View Article : Google Scholar : PubMed/NCBI
7	Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J and Burchell J: A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem. 263:12820–12823. 1988.PubMed/NCBI
8	Hansen J, Martin P and Nowinski R: Monoclonal antibodies identifying a novel T-Cell antigen and Ia antigens of human lymphocytes. Immunogenetics. 10:247–260. 1980. View Article : Google Scholar
9	Wright SE, Khaznadar R, Wang Z, Quinlin IS, Rewers-Felkins KA, Phillips CA and Patel S: Generation of MUC1-stimulated mononuclear cells using optimized conditions. Scand J Immunol. 67:24–29. 2008.PubMed/NCBI
10	Wright SE, Rewers-Felkins KA, Quinlin IS, Eldridge PW, Zorsky PE, Klug PP, Phillips CA and Philip R: Adoptive immunotherapy of mucin1 expressing adenocarcinomas with mucin1 stimulated human peripheral blood mononuclear cells. Int J Mol Med. 9:401–404. 2002.PubMed/NCBI
11	Wright SE, Kilinski L, Talib S, Lowe KE, Burnside JS, Wu JY, Dolby N, Dombrowski KE, Lebkowski JS and Philip R: Cytotoxic T lymphocytes from humans with adenocarcinomas stimulated by native MUC1 mucin and a mucin peptide mutated at a glycosylation site. J Immunother. 23:2–10. 2000. View Article : Google Scholar : PubMed/NCBI
12	Wright SE, Rewers-Felkins K A, Quinlin IS, Fogler WE, Phillips CA, Townsend M, Robinson W and Philip R: MHC-unrestricted lysis of MUC1-expressing cells by human peripheral blood mononuclear cells. Immunol Invest. 37:215–225. 2008.
13	Alajez NM, Schmielau J, Alter MD, Cascio M and Finn OJ: Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution. Blood. 105:4583–4589. 2005. View Article : Google Scholar : PubMed/NCBI
14	Kanof ME and Smith PD: Preparation of human mononuclear cell populations and subpopulations. Current Protocols in Immunology. Coligan JE: (New York, NY, USA). John Wiley & Sons, Inc. 71994.
15	Zhai YF, Esselman WJ, Oakley CS, Chang CC and Welsch CW: Growth of MCF-7 human breast carcinoma in severe combined immunodeficient mice: Growth suppression by recombinant interleukin-2 treatment and role of lymphokine-activated killer cells. Cancer Immunol Immunother. 35:237–245. 1992. View Article : Google Scholar : PubMed/NCBI
16	Wunderlich J: Chromium Release Cytoxicity Assay. Current Protocols in Immunology. Coligan JE: (New York, NY, USA). John Wiley & Sons, Inc. 31994.
17	Levine BL, Bernstein WB, Connors M, Craighead N, Lindsten T, Thompson CB and June CH: Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J Immunol. 159:5921–5930. 1997.PubMed/NCBI
18	Frigault MJ, Lee J, Basil MC, Carpenito C, Motohashi S, Scholler J, Kawalekar OU, Guedan S, McGettigan SE, Posey AD Jr, et al: Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol Res. 3:356–367. 2015. View Article : Google Scholar : PubMed/NCBI
19	Künkele A, Johnson AJ, Rolczynski LS, Chang CA, Hoglund V, Kelly-Spratt KS and Jensen MC: Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas-FasL-Dependent AICD. Cancer Immunol Res. 3:368–379. 2015. View Article : Google Scholar : PubMed/NCBI
20	Kalamasz D, Long SA, Taniguchi R, Buckner JH, Berenson RJ and Bonyhadi M: Optimization of human T-cell expansion ex vivo using magnetic beads conjugated with anti-CD3 and Anti-CD28 antibodies. J Immunother. 27:405–418. 2004. View Article : Google Scholar : PubMed/NCBI
21	Li Y and Kurlander RJ: Comparison of anti-CD3 and anti-CD28-coated beads with soluble anti-CD3 for expanding human T cells: Differing impact on CD8 T cell phenotype and responsiveness to restimulation. J Transl Med. 8:1042010. View Article : Google Scholar : PubMed/NCBI
22	Maus MV, Thomas AK, Leonard DGB, Allman D, Addya K, Schlienger K, Riley JL and June CH: Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol. 20:143–148. 2002. View Article : Google Scholar : PubMed/NCBI
23	Singh H, Figliola MJ, Dawson MJ, Olivares S, Zhang L, Yang G, Maiti S, Manuri P, Senyukov V, Jena B, et al: Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. PLoS One. 8:e641382013. View Article : Google Scholar : PubMed/NCBI